Company Presentation July 2020 :IN www.inmedpharma.com :IMLFF - PowerPoint PPT Presentation

U N L O C K I N G T H E P O T E N T I A L O F C A N N A B I N O I D M E D I C I N E S Company Presentation July 2020 :IN www.inmedpharma.com :IMLFF

Disclaimers This presentation does not constitute an offering to sell or a solicitation of an offer to buy securities and the information contained herein is subject to the information contained in the Company’s continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and operations of the Company included in this presentation has been prepared in accordance with Canadian standards and is not comparable in all respects to similar information for United States companies. In addition, any financial information included in this presentation has been prepared in Canadian dollars, except as otherwise indicated, and is subject to applicable Canadian generally accepted accounting principles and Canadian auditing and auditor independence standards, which differ from United States generally accepted accounting principles and United States auditing and auditor independence standards in certain material respects. The information provided in this presentation is not intended to provide financial, tax, legal or accounting advice. The Company exists under the laws of the Province of British Columbia, Canada. A substantial portion of the Company’s assets are located outside the United States. As well, some of the Company’s officers and directors are residents of Canada. As a result, it may be difficult for investors to enforce civil liabilities under United States federal or state securities laws. Company Presentation July2020 2

Forward Looking Statements This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including, among others, statements concerning: unlocking the full potential of cannabinoid pharmaceuticals; anticipated clinical development activities, timelines, catalysts, and milestones; the potential benefits of product candidates; anticipated revenue and market opportunities; and the continued availability of key personnel. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. With respect to the forward-looking information contained in this presentation, the Company has made numerous assumptions regarding, among other things: continued and timely positive preclinical and clinical efficacy data; the speed of regulatory approvals; demand for the Company’s products; continued availability of key personnel; continued access to sufficient capital to fund operations; and continued economic and market stability. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others: the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results; risks associated with obtaining funding from third parties; risks related to the timing and costs of clinical trials; key personnel may become unable to serve the Company; the need for receipt of regulatory approvals; and economic and market conditions may worsen. Readers are cautioned that the foregoing list is not exhaustive. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s annual information form dated September 26, 2019, a copy of which is available on SEDAR at www.sedar.com. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, except as required by law. Company Presentation July2020 3

Experienced Executive Team Bruce S. Colwill, CPA,CA Alexandra Mancini, MSc Eric A. Adams, MIBS Chief Financial Officer SVP , Clinical and Regulatory Affairs Chief Executive Officer 30+ years of experience in global biopharma 25+ years of financial leadership with private and public 30+ years of global biopharma R&D experience, leadership: business development, sales, marketing, companies; executing IPO, equity and debt financings overseeing drug development with Sirius and M&A with enGene, QLT, Abbott, Fresenius General Fusion, Entrée Resources, Neuromed Pharma Genomics, Inex Pharmaceuticals, and QLT Eric Hsu, PhD Michael Woudenberg,PEng SVP , Preclinical R&D Vice President, CMC 20+ years of scientific leadership experience with 20+ years of engineering, scale-up and GMP enGene in gene transfer technologies, formulation manufacturing experience with Phyton Biotech, and process development Arbutus Biopharma, 3M and CardiomePharma Company Presentation July2020 4

A Differentiated Cannabinoid Pharmaceutical Company Focused on the Therapeutic Application of Cannabinoids for the Treatment of Diseases with High Unmet Medical Needs Researching the therapeutic potential of rare cannabinoids, beyond THC & CBD, beginning with cannabinol ( CBN ) Selecting innovative, topically applied cannabinoid therapies where we can establish a proprietary foothold in treating diseases with high unmet medical needs, starting with dermatology and ocular diseases Developing IntegraSyn ä - a flexible, integrated cannabinoid manufacturing system using novel enzyme(s) to efficiently produce bio-identical, economical, pharmaceutical-grade cannabinoids. Company Presentation July2020 5

The Opportunity & Challenge of Rare Cannabinoids <1% 2–20% Major Cannabinoids 100+ Rare Cannabinoids THC CBD CBN, CBG, CBGA, CBGV, CBGVA, THCV, THCVA, CBC, CBCV, CBCVA, CBDV, CBC, CBCA, CBNA… • Epilepsy • Inflammation • The 100+ rare cannabinoids occur in • Anxiety • Nausea extremely low amounts in the cannabis plant • Stress • Stress Disorder Disorder • The cost of extracting sufficient quantities of these cannabinoids can be prohibitive • Pain • Sleep Apnea • The challenge is how to manufacture sufficient quantity & purity to investigate, and potentially commercialize, rare cannabinoid-based therapies Note: lists are not exhaustive Company Presentation July2020 6

Limitations of Traditional Cannabinoid Production Approaches EXTRACTION CHEMICAL SYNTHESIS BIOSYNTHESIS • Access to rare cannabinoids • May not produce bio-identical • Bioburden/stress on microbe prohibitively expensive cannabinoid depending on may limit final yields cannabinoid complexity • Limited quantity in the plant • Separation and purification • Potential for significant yield loss challenges to isolate • Plant > Grow > Harvest > Extract > due to purification / removal of cannabinoid from mixture Purify process is resource the non-bio-identical intensive, large carbon footprint • Process costs / complexity cannabinoids increase with each new • Much longer cycle time • Complicated and costly scale-up cannabinoid • Quality/consistency issues, due to purification techniques pesticide removal challenges may result in import/export restrictions Company Presentation July2020 7

IntegraSyn™: Biosynthesis Evolved IntegraSyn™ is InMed’s integrated cannabinoid manufacturing approach Minimizes bioburden Commonly available Flexibility Optimized steps to Transferable on fermentation and cost-efficient to shift from produce high-yield, technology microbe starting materials production of one pharma-grade to facilitate scale-up, cannabinoid to a cannabinoids manufacturing range of cannabinoids at commercial scale and supply Company Presentation July2020 8

Cost-Efficient Cannabinoid Production with IntegraSyn TM Upstream Processing Downstream Purification Crude Enzyme Cannabinoid Drying Mixture E. coli Enzymatic Reaction Separation of Cannabinoid from Fermentation Reaction Mixture BIOSYNTHESIS BIOTRANSFORMATION PURIFICATION ● Flexible Path 1 ● Modular CHEMICAL SYNTHESIS ● Cost-Efficient Further API Grade ● Scalable Path 2 Path 1 Cannabinoid OR Cannabinoid or Production Path 2 Company Presentation July2020 9

Cannabinoid Manufacturing: Competitive Landscape Algae/Other Yeast Biosynthesis IntegraSyn TM KEY PARTNERSHIPS R&D Commercial A flexible, integrated cannabinoid Chemical Synthesis synthesis approach using a novel enzyme(s) and various standard pharma manufacturing processes to efficiently produce bio-identical, economical, GMP-grade cannabinoids. Note: lists are not exhaustive Company Presentation July2020 10

From Biosynthesis to IntegraSyn TM : High-level Time & Event Schedule 2019 1H 2020 2H 2020 HPLC assay tech transfer to NRC PCT application filed Conduct analytical assay development to Up-stream fermentation tech transfer to NRC support batch Continue scale-up of production Bioreactor fermentation condition optimization IntegraSyn TM process with Almac Scale-up process to be Processing of patent applications GMP ready Finalize USP development at NRC Optimize pathways for DSP development at Almac production of other cannabinoids Conduct alternative process studies at Almac Identify potential Decision on future manufacturing pathway partnership opportunities Completed Pending USP – Up-stream Process (Fermentation); DSP – Down-stream Process (Purification); GMP – Good Manufacturing Practices; NRC – National Research Council of Canada; CDMO – Contract Development and Manufacturing Organization Company Presentation July2020 11